{
    "Trade/Device Name(s)": [
        "NucliSENS EasyQ Enterovirus v1.1 Assay",
        "NucliSENS EasyQ Enterovirus v1.1",
        "NucliSENS EasyQ Enterovirus Controls",
        "NucliSENS EasyQ Analyzer",
        "NucliSENS EasyQ Director Software 2.5",
        "NucliSENS EasyQ Incubator",
        "NucliSENS miniMAG",
        "NucliSENS Lysis Buffer 48T",
        "NucliSENS Magnetic Extraction Reagents"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K063261",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OAI"
    ],
    "Summary Letter Date": "June 23, 2008",
    "Summary Letter Received Date": "May 1, 2008",
    "Submission Date": "April 30, 2008",
    "Regulation Number(s)": [
        "21 CFR 866.3225"
    ],
    "Regulation Name(s)": [
        "Nucleic acid amplification assay system, enterovirus (EV) RNA"
    ],
    "Analyte Class(es)": [
        "virology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Enterovirus RNA"
    ],
    "Specimen Type(s)": [
        "Cerebrospinal fluid"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "NucliSENS EasyQ System",
        "NucliSENS EasyQ Analyzer",
        "NucliSENS EasyQ Director Software",
        "NucliSENS EasyQ Incubator",
        "NucliSENS miniMAG"
    ],
    "Method(s)/Technology(ies)": [
        "Nucleic acid amplification",
        "NASBA",
        "Fluorescent molecular beacon detection"
    ],
    "Methodologies": [
        "Nucleic acid sequence-based amplification (NASBA)",
        "Real-time fluorescence detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "Analyzer",
        "Software",
        "Incubator",
        "Extraction kit",
        "Reagent",
        "Lysis Buffer",
        "Magnetic Extraction Reagents"
    ],
    "Document Summary": "FDA 510(k) summary for NucliSENS EasyQ Enterovirus v1.1 qualitative nucleic acid amplification assay to detect enterovirus RNA in CSF using NASBA and fluorescence detection.",
    "Indications for Use Summary": "Qualitative detection of Enterovirus RNA in CSF from patients with signs and symptoms of meningitis, as an aid in the presumptive laboratory diagnosis of enterovirus infection in pediatric patients suspected of aseptic meningitis or meningoencephalitis.",
    "fda_folder": "Microbiology"
}